Drug-drug Interactions
DDIs were analyzed using Micromedex® (Watson health, IBM Corporation), and categorized on the basis of severity (contraindicated, major, moderate, minor) and documentation (excellent, good, fair). DDIs were included in the analyses if they fit into either of two categories: Category 1: severity of contraindicated, or severity of major with excellent/good documentation; or Category 2: severity of moderate with excellent/good documentation. DDI that did not satisfy criteria for inclusion in category 1 or 2 were not included in these analyses. DDIs were also screened for clinical relevance by Lexicomp® (Wolters Kluwer Health, Hudson, OH), based on having a severity category D or X, which was selected due to its superior performance for detecting clinically relevant DDIs.17 Commonly identified DDIs were further included for analysis. Finally, DDI that generated an alert in MiChart were classified as having been detected by the EMR (Figure 1).